Allergy Shot for Pollen: Single vs Polysensitized — Finding the Right Option

Yes — SCIT can be formulated as a single-allergen extract if IgE testing confirms monosensitization and that allergen is the clinically relevant driver. A single-allergen vial actually has advantages: simpler extract composition, fewer allergen interactions, and more predictable dose escalation. For timothy grass and short ragweed monosensitization, FDA-approved SLIT tablets (Grastek and Ragwitek respectively) are designed exactly for this scenario and are an alternative to injection-based SCIT. Your allergist should confirm true monosensitization via a comprehensive IgE panel before proceeding with single-allergen immunotherapy — approximately 70% of patients presenting as 'single-allergen allergic' have additional sensitizations discovered on comprehensive testing.

Grastek (ALK, timothy grass) is FDA-approved allergen immunotherapy for timothy grass-induced allergic rhinitis, but it is a sublingual tablet, not an injection. It is taken daily as a tablet dissolved under the tongue. It requires one supervised first-dose visit in a medical setting to monitor for anaphylaxis, after which it is taken at home daily for 3–5 years. Grastek carries a boxed warning for anaphylaxis and requires co-prescription of an epinephrine auto-injector. It is approved for ages 5–65. Like injectable SCIT, it is disease-modifying — not merely symptomatic. For patients who are monosensitized to timothy grass and prefer daily oral dosing to weekly clinic visits, Grastek or its 5-grass equivalent Oralair is often the recommended option.

Not necessarily — if true short ragweed monosensitization is confirmed and the seasonal impact on quality of life warrants treatment, the FDA-approved Ragwitek SLIT tablet (Merck, ages 5–65 after 2021 expansion) is a targeted option for ragweed monosensitization. Ragwitek is taken as a daily sublingual tablet at home (after one supervised first dose), requires epinephrine co-prescription, and carries a boxed warning for anaphylaxis. If you prefer injections, compounded ragweed SCIT using FDA-standardized short ragweed extract (Amb a 1) is an equivalent option. The decision between SLIT tablet and SCIT is based on patient preference, lifestyle, and allergist recommendation.

Oral allergy syndrome (OAS, also called pollen-food syndrome) is IgE cross-reactivity between pollen proteins and structurally similar proteins in raw fruits and vegetables. In birch-sensitized patients, Bet v 1 (the major birch allergen) cross-reacts with Mal d 1 (raw apple), Cor a 1 (hazelnut), Pru av 1 (cherry), and Pru p 1 (peach) — producing tingling, itching, and mild swelling of the lips and mouth when these foods are eaten raw. Cooking destroys most PR-10 epitopes, which is why the same patient who cannot bite a raw apple can usually eat cooked apple or applesauce without symptoms. Birch SCIT has been reported in observational studies to reduce OAS symptoms in some patients, but RCT evidence for SCIT as an OAS treatment is limited. OAS alone is generally not a primary indication for SCIT.

No — multiple pollen sensitizations are typically addressed in a single multi-allergen SCIT vial. A board-certified allergist compiles the extract for all clinically relevant sensitized pollens (e.g., birch + timothy grass + short ragweed + oak) into one custom vial. Some incompatible allergen combinations may be separated into two vials to prevent extract degradation, but the injection schedule remains the same. For polysensitized patients, SCIT remains the primary option because FDA-approved SLIT tablets cover only specific single allergens (Grastek timothy, Oralair 5-grass, Ragwitek ragweed) and cannot address tree pollen or weed sensitizations beyond ragweed.

SCIT can be formulated with oak pollen extract (non-standardized) and is used clinically. No FDA-standardized oak extract exists. Oak sensitization frequently co-occurs with birch sensitization via the PR-10 / Bet v 1 protein family — they share IgE cross-reactive epitopes. In patients with primary birch sensitization who also test positive for oak, birch SCIT often provides cross-protective benefit for oak-triggered symptoms as well. An allergist reviewing your IgE component results (Bet v 1, Que a 1) can clarify whether separate oak extract is needed or whether birch SCIT will address the oak component through cross-reactivity.